IDENIX PHARM
Norcod AS engages in the farming, production, operation, distribution, marketing, and sale of farmed cod products in Norway and internationally. The company was incorporated in 2018 and is headquartered in Trondheim, Norway.
IDENIX PHARM (NO9) - Total Liabilities
Latest total liabilities as of September 2025: €448.72 Million EUR
Based on the latest financial reports, IDENIX PHARM (NO9) has total liabilities worth €448.72 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
IDENIX PHARM - Total Liabilities Trend (2019–2024)
This chart illustrates how IDENIX PHARM's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
IDENIX PHARM Competitors by Total Liabilities
The table below lists competitors of IDENIX PHARM ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Proteomics International Laboratories Ltd
AU:PIQ
|
Australia | AU$1.81 Million |
|
Wafangdian Bearing Co Ltd
SHE:200706
|
China | HK$2.78 Billion |
|
SRG Mining Inc
PINK:SRGMF
|
USA | $642.06K |
|
Sino Horizon Holdings Ltd
TW:2923
|
Taiwan | NT$70.89 Billion |
|
Alves Kablo San As
IS:ALVES
|
Turkey | TL1.57 Billion |
|
Southern Acids (M) Bhd
KLSE:5134
|
Malaysia | RM232.27 Million |
|
Astro Malaysia Holdings Bhd
KLSE:6399
|
Malaysia | RM3.84 Billion |
|
Korea Ind
KO:002140
|
Korea | ₩165.56 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down IDENIX PHARM's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IDENIX PHARM's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IDENIX PHARM (2019–2024)
The table below shows the annual total liabilities of IDENIX PHARM from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | €517.89 Million | +10.19% |
| 2023-09-30 | €469.99 Million | +28.70% |
| 2022-09-30 | €365.17 Million | +47.67% |
| 2021-09-30 | €247.28 Million | +224.51% |
| 2020-09-30 | €76.20 Million | +1033.77% |
| 2019-09-30 | €6.72 Million | -- |